The COVID-19 pandemic has thrusted the critical importance of better understanding how infectious outbreaks affect our patients -- particularly potentially more vulnerable patients with inflammatory bowel diseases (IBD) -- and evaluating strategies to mitigate their destructive potential.
We are currently conducting several multi-center studies related to COVID-19.
We are also partnering with other UCLA departments on the development of an innovative tool for airborne particle containment to reduce risk of exposure to healthcare workers.
Berkeley Limketkai, MD, PhD, director of clinical research for the Center for Inflammatory Bowel Diseases, is conducting a study the impact of the COVID-19 pandemic on patients with IBD in comparing them to individuals without IBD.
You may be eligible if you:
Survey will measure:
Please help us in learning more about how COVID-19 may have impacted you.
Infection risk perception among patients with inflammatory bowel diseases - IRB#20-001078 6/22/20 - no expiration - SGIRB